Pierce™ 抗-DYKDDDDK 磁性琼脂糖
Invitrogen17万+抗体限时买二赠一，靶点广，灵活用！
Pierce™ 抗-DYKDDDDK 磁性琼脂糖
引用和文献 (8)
Thermo Scientific™

Pierce™ 抗-DYKDDDDK 磁性琼脂糖

Thermo Scientific Pierce 抗-DYKDDDDK 磁性琼脂糖是一种从体外蛋白表达系统、细菌、酵母菌和哺乳动物细胞中进行 DYKDDDDK 标签蛋白纯化和免疫沉淀 (IP)了解更多信息
Have Questions?
更改视图buttonViewtableView
货号数量
A367974 mL
A3679820 mL
货号 A36797
价格（CNY)
3,574.00
飞享价
Ends: 27-Dec-2025
5,758.00
共减 2,184.00 (38%)
Each
添加至购物车
数量:
4 mL
价格（CNY)
3,574.00
飞享价
Ends: 27-Dec-2025
5,758.00
共减 2,184.00 (38%)
Each
添加至购物车
Thermo Scientific Pierce 抗-DYKDDDDK 磁性琼脂糖是一种从体外蛋白表达系统、细菌、酵母菌和哺乳动物细胞中进行 DYKDDDDK 标签蛋白纯化和免疫沉淀 (IP) 的快速便捷方法。氨基酸序列 DYKDDDDK（通常称为 FLAG）被高亲和力大鼠单克隆抗体（克隆 L5）识别，该抗体与磁石嵌入的琼脂糖核心颗粒共价连接。

对于蛋白纯化，将磁性琼脂糖添加到含有 DYKDDDDK 标签蛋白的样品中，其中标签位于 N 或 C 端。然后，将捕获的蛋白与上清液磁性分离，洗去非特异性结合蛋白，然后用洗脱缓冲液分离结合的 DYKDDDDK 标签蛋白。使用磁力架或 KingFisher Flex 磁粒子处理器等仪器从溶液中去除磁性琼脂糖。自动仪器对于更高通量的纯化和纯化条件筛选特别有用。

特点包括：
特异性 — 独特的碱基微珠和高特异性抗体可较大限度地减少脱靶结合（低非特异性结合）
高纯度 — 优化的结合-洗涤-洗脱方案可以实现高纯度
高得率 — 特殊抗体偶联方法可实现高得率
快速 — 整个纯化方案通常只需不到40分钟
经济 — 纯化方案能够多次重复使用
通用 — 微珠兼容手动和自动化工作流程（例如 KingFisher 仪器）

Pierce 抗 DYKDDDDK 磁性琼脂糖的特性：

组成：抗 DYKDDDDK 抗体与磁性、高度交联的琼脂糖载体共价连接
磁化：亚铁磁性，剩磁较低
微珠大小：10–40 µm
微珠浓度：25% 浆液（溶于磷酸盐缓冲盐水）、0.01% Tween-20 去污剂、0.02% 叠氮化钠，pH 值为7.2
结合能力：≥3.2 mg DYKDDDDK-tGFP-His 蛋白 (∼32 kDa)/mL 沉淀微珠

仅供科研使用。不可用于诊断程序。
规格
柱床容量1 mL
容量4 mL
形式液体
产品规格液体
配方Slurry: 25%
粒径25 to 30 μm
产品线Pierce
产品类型磁性琼脂糖
数量4 mL
运输条件湿冰
固定相抗-DYKDDDDK 单克隆抗体
基质Magnetic Agarose
Unit SizeEach
内容与储存
1 mL 沉淀微珠。4 mL，以 25% 悬浮液（溶于含 0.02% 叠氮化钠的 PBS）形式提供。

在 2–8°C 下储存。

常见问题解答 (FAQ)

How does Pierce Anti-DYKDDDDK Magnetic Agarose (Cat. No. A36797, A36798) work for purification of DYKDDDK-tagged recombinant proteins?

The amino acid sequence DYKDDDDK, commonly known as the ''Flag'' epitope group, is recognized by a high-affinity rat monoclonal antibody (clone L5) that is covalently attached to a magnetite-embedded agarose core particle.

For protein purification, the magnetic agarose is added to a sample containing DYKDDDDK-tagged proteins with the tag on either the N- or the C-terminus. Captured proteins are then magnetically separated from the supernatant, and non-specifically bound proteins can be washed away before dissociating bound DYKDDDDK-tagged proteins with elution buffer. The magnetic agarose is removed from the solution using a magnetic stand or an instrument such as the KingFisher Flex Magnetic Particle Processor. Automated instruments are especially useful for higher-throughput purifications and screening of purification conditions.

Find additional tips, troubleshooting help, and resources within our Protein Purification and Isolation Support Center.

What is the slurry/suspension percentage for your anti-DYKDDDDK ("FLAG") products?

Anti-DYKDDDDK Magnetic Agarose (Cat. Nos. A36797, A36798, A36799B) is offered as a 25% suspension (1 mL of 25% suspension = 0.25 mL of settled beads). UltraLink-based Anti-DYKDDDDK Affinity Resin (Cat. Nos, A36801, A36803, A36804) is offered as a 50% slurry (1 mL of 50% slurry = 0.5 mL of settled resin).

Find additional tips, troubleshooting help, and resources within our Protein Purification and Isolation Support Center.

What is the binding capacity for your Anti-DYKDDDDH Magnetic Agarose?

Here is the binding capacity: ≥3.2 mg DYKDDDDK-tGFP-His protein (˜32kDa)/mL settled beads.

Find additional tips, troubleshooting help, and resources within our Protein Purification and Isolation Support Center.

How do I cleave off the DYKDDDDK ("FLAG") tag after purification?

An enterokinase cleavage site behind the DYKDDDDK (“FLAG”) tag can allow complete removal of the DYKDDDDK (“FLAG”) tag leaving no additional amino acids. We offer EKMax Enterokinase (Cat. Nos. E18001 and E18002) that can be used for this purpose. Subsequently, the EKMax Enterokinase can be removed using EK-Away Resin (Cat. No. R18001), a resin conjugated with soybean trypsin inhibitor, which has high affinity for enterokinase.

Find additional tips, troubleshooting help, and resources within our Protein Purification and Isolation Support Center.

引用和文献 (8)

引用和文献
Abstract
NUMA1 modulates apoptosis of esophageal squamous cell carcinoma cells through regulating ASK1-JNK signaling pathway.
Authors:Yin S,Zhao S,Li J,Liu K,Ma X,Zhang Z,Wang R,Tian J,Liu F,Song Y,Song M,Zhao R,Yang R,Lee MH,Dong Z
Journal:Cellular and molecular life sciences : CMLS
PubMed ID:37462735
Esophageal squamous cell carcinoma (ESCC) is a common malignancy worldwide with a low survival rate due to a lack of therapeutic targets. Here, our results showed that nuclear mitotic apparatus protein 1 (NUMA1) transcript and protein levels are significantly upregulated in ESCC patient samples and its high expression predicated poor ... More
A protein complex of LCN2, LOXL2 and MMP9 facilitates tumour metastasis in oesophageal cancer.
Authors:Xia Q,Du Z,Chen M,Zhou X,Bai W,Zheng X,Lin L,Zhao Y,Ding J,Wu Z,Zou H,Wang S,Xu L,Li E,Wu B
Journal:Molecular oncology
PubMed ID:37753805
During malignant tumour development, the extracellular matrix (ECM) is usually abnormally regulated. Dysregulated expression of lysyl oxidase-like 2 (LOXL2), matrix metalloproteinase 9 (MMP9) and lipocalin 2 (LCN2) are associated with ECM remodelling. In this study, protein-protein interaction assays indicated that LCN2 and LOXL2 interactions and LCN2 and MMP9 interactions occurred ... More
RUFY3 and RUFY4 are ARL8 effectors that promote coupling of endolysosomes to dynein-dynactin.
Authors:Keren-Kaplan T,Sarić A,Ghosh S,Williamson CD,Jia R,Li Y,Bonifacino JS
Journal:Nature communications
PubMed ID:35314674
The small GTPase ARL8 associates with endolysosomes, leading to the recruitment of several effectors that couple endolysosomes to kinesins for anterograde transport along microtubules, and to tethering factors for eventual fusion with other organelles. Herein we report the identification of the RUN- and FYVE-domain-containing proteins RUFY3 and RUFY4 as ARL8 ... More
Immunoprecipitation Strategies to Isolate RIPK1/RIPK3 Complexes in Mouse Macrophages
Authors:Siokas I, Zhang D, Poltorak A, Muendlein H, Degterev A
Journal:Curr Protoc.
PubMed ID:
Helicase-inactivating BRIP1 mutation yields Fanconi anemia with microcephaly and other congenital abnormalities
Authors:Kamal L, Pierce SB, Canavati C, Rayyan AA, Jaraysa T, Lobel O, Lolas S, Norquist BM, Rabie G, Zahdeh F, Levy-Lahad E, King M-C, Kanaan, MN
Journal:Cold Spring Harb Mol Case Stud
PubMed ID:
View all Pierce™ 抗-DYKDDDDK 磁性琼脂糖 citations